Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of GL-V9 in preparation of medicine for preventing and/or treating sepsis

A technology of GL-V9 and sepsis, which is applied in the direction of pharmaceutical formulations, antibacterial drugs, medical preparations containing active ingredients, etc., can solve the problems of tissue damage and damage to normal physiological functions of the body, and reduce the release of inflammatory factors , restore macrophage viability, and inhibit cytotoxic damage

Inactive Publication Date: 2021-12-14
CHINA PHARM UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the persistent existence of inflammatory response will lead to tissue damage and impair the normal physiological function of the body.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GL-V9 in preparation of medicine for preventing and/or treating sepsis
  • Application of GL-V9 in preparation of medicine for preventing and/or treating sepsis
  • Application of GL-V9 in preparation of medicine for preventing and/or treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 GL-V9 can reduce the degree of pyroptosis and significantly restore the macrophage J774A.1 induced by liposome 2000 transfection of lipopolysaccharide LPS into macrophages and Escherichia coli infection of macrophages Decreased cell viability and increased cytotoxic damage.

[0029] 1. Experimental materials

[0030] (1) Drugs

[0031] GL-V9(C 24 h 27 o 5 N, molecular weight: 409.47) provided by China Pharmaceutical University, light yellow powder with a purity of 98%, prepared into a mother liquor with DMSO, and stored at -20°C. Dilute to the required working concentration before use.

[0032] (2) cell line

[0033] The mouse mononuclear macrophage cell line J774A.1 was purchased from the cell bank of the Institute of Biochemistry and Cell Biology, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, and cultured in DMEM medium containing 10% fetal bovine serum.

[0034] (3) Reagents

[0035] 1) Culture medium: DMEM medium was purch...

Embodiment 2

[0089] Example 2 GL-V9 can reduce the mortality rate of cecal ligation and puncture (CLP) model mice, improve organ function damage and inhibit the release of inflammatory factors.

[0090] 1. Experimental materials

[0091] (1) Drugs:

[0092] GL-V9 is provided by Jiangsu Provincial Key Laboratory of Tumor Occurrence and Intervention, Jiangsu Pharmaceutical University. The purity is over 99%. Transparent yellow liquid for intraperitoneal injection.

[0093] (2) Reagents

[0094] 1) ELISA kits for mouse IL-1β, IL-6, IL-18 and TNF-α: Wuhan Aibotec Biotechnology Co., Ltd.

[0095] (3) Experimental animals

[0096] Source, species, and strain: C57BL / 6J mice, provided by Changzhou Cavens Experimental Animal Co., Ltd. (Experimental animal production license: SCXK (Su) 2016-0011).

[0097] Age: 6-8 weeks

[0098] Weight: 18-22g

[0099] Gender: Male

[0100] 2. Experimental method:

[0101] (1) Grouping of experimental animals

[0102]

[0103] (2) Cecal ligation and pu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of GL-V9 in preparation of a medicine for preventing and / or treating sepsis. Compared with the prior art, it is found that in an in-vitro experiment, the GL-V9 can be used for remarkably recovering J774A.1 cell viability decline and increased cytotoxic damage caused by two ways of transfecting lipopolysaccharide (LPS) into macrophages by lipidosome 2000 and infecting the macrophages by Escherichia coli to cause pyroptosis, and inhibiting the expression condition of the pyroptosis related protein mediated by the Caspase-11. In in-vivo experiments, the GL-V9 can reduce the death rate of cecum ligation paracentesis (CLP) sepsis model mice, weaken organ function damage and inhibit release of inflammatory factors. The effects show that the GL-V9 can be used for treating sepsis and has a medicine development prospect.

Description

technical field [0001] The invention discloses the application of wogonin derivative GL-V9 in the preparation of medicines for preventing and / or treating sepsis, and belongs to the technical field of new uses of GL-V9. Background technique [0002] Inflammation is a basic pathological process that occurs when biological tissues are stimulated by injury factors such as trauma and infection. Inflammation has long been considered a mechanism for the body to protect itself. However, the persistent existence of inflammatory response will lead to tissue damage and impair the normal physiological function of the body. [0003] Sepsis is a life-threatening organ dysfunction disease caused by dysregulation of the body's response to infection. The course of sepsis develops rapidly, the condition is serious, and the case fatality rate is high. It is currently one of the leading causes of death worldwide. Generally, sepsis can be caused by infection anywhere in the body, including s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4025A61P31/04
CPCA61K31/4025A61P31/04
Inventor 卢娜赵越卜修民郭青龙赵凯
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com